|
1
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokoch GM: Biology of the p21-activated
kinases. Annu Rev Biochem. 72:743–781. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Radu M, Semenova G, Kosoff R and Chernoff
J: PAK signalling during the development and progression of cancer.
Nat Rev Cancer. 14:13–25. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abo A, Qu J, Cammarano MS, Dan C, Fritsch
A, Baud V, Belisle B and Minden A: PAK4, a novel effector for
Cdc42Hs, is implicated in the reorganization of the actin
cytoskeleton and in the formation of filopodia. EMBO J.
17:6527–6540. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dan C, Kelly A, Bernard O and Minden A:
Cytoskeletal changes regulated by the PAK4 serine/threonine kinase
are mediated by LIM kinase 1 and cofilin. J Biol Chem.
276:32115–32121. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qu J, Li X, Novitch BG, Zheng Y, Kohn M,
Xie JM, Kozinn S, Bronson R, Beg AA and Minden A: PAK4 kinase is
essential for embryonic viability and for proper neuronal
development. Mol Cell Biol. 23:7122–7133. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tian Y, Lei L, Cammarano M, Nekrasova T
and Minden A: Essential role for the Pak4 protein kinase in
extraembryonic tissue development and vessel formation. Mech Dev.
126:710–720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cammarano MS, Nekrasova T, Noel B and
Minden A: Pak4 induces premature senescence via a pathway requiring
p16INK4/p19ARF and mitogen-activated protein
kinase signaling. Mol Cell Biol. 25:9532–9542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Minden A: The pak4 protein kinase in
breast cancer. ISRN Oncol. 2012:6942012012.PubMed/NCBI
|
|
11
|
Yang JX, Han YJ, Zheng H and Luo RC:
Expression of PAK4 in breast cancer and benign breast pathological
changes. Nan Fang Yi Ke Da Xue Xue Bao. 30:981–983. 2010.(In
Chinese). PubMed/NCBI
|
|
12
|
Wang C, Li Y, Zhang H, Liu F, Cheng Z,
Wang D, Wang G, Xu H, Zhao Y, Cao L, et al: Oncogenic PAK4
regulates Smad2/3 axis involving gastric tumorigenesis. Oncogene.
33:3473–3484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Zhang Y, Li Z, Wang X, Qu X and Liu
Y: Activated Pak4 expression correlates with poor prognosis in
human gastric cancer patients. Tumour Biol. 36:9431–9436. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP and
Liu LY: MicroRNA-433 inhibits cell proliferation in hepatocellular
carcinoma by targeting p21 activated kinase (PAK4). Mol Cell
Biochem. 399:77–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shu XR, Wu J, Sun H, Chi LQ and Wang JH:
PAK4 confers the malignance of cervical cancers and contributes to
the cisplatin-resistance in cervical cancer cells via PI3K/AKT
pathway. Diagn Pathol. 10:1772015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tyagi N, Marimuthu S, Bhardwaj A, Deshmukh
SK, Srivastava SK, Singh AP, McClellan S, Carter JE and Singh S:
p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes
in pancreatic cancer cells through activation of STAT3 signaling.
Cancer Lett. 370:260–267. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nekrasova T and Minden A: PAK4 is required
for regulation of the cell-cycle regulatory protein p21, and for
control of cell-cycle progression. J Cell Biochem. 112:1795–1806.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wells CM, Whale AD, Parsons M, Masters JR
and Jones GE: PAK4: A pluripotent kinase that regulates prostate
cancer cell adhesion. J Cell Sci. 123:1663–1673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Lock JG, Olofsson H, Kowalewski JM,
Teller S, Liu Y, Zhang H and Strömblad S: Integrin-mediated cell
attachment induces a PAK4-dependent feedback loop regulating cell
adhesion through modified integrin alpha v beta 5 clustering and
turnover. Mol Biol Cell. 21:3317–3329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak
VC, Ngan HY, Wong OG, Zhang HQ and Cheung AN: Overexpressed PAK4
promotes proliferation, migration and invasion of choriocarcinoma.
Carcinogenesis. 32:765–771. 2011.PubMed/NCBI
|
|
21
|
Paliouras GN, Naujokas MA and Park M:
Pak4, a novel Gab1 binding partner, modulates cell migration and
invasion by the Met receptor. Mol Cell Biol. 29:3018–3032. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Chen N, Cui X, Zheng X, Deng L,
Price S, Karantza V and Minden A: The protein kinase Pak4 disrupts
mammary acinar architecture and promotes mammary tumorigenesis.
Oncogene. 29:5883–5894. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Franovic A, Elliott KC, Seguin L, Camargo
MF, Weis SM and and Cheresh DA: Glioblastomas require integrin
αvβ3/PAK4 signaling to escape senescence. Cancer Res. 75:4466–4473.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Murray BW, Guo C, Piraino J, Westwick JK,
Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, et
al: Small-molecule p21-activated kinase inhibitor PF-3758309 is a
potent inhibitor of oncogenic signaling and tumor growth. Proc Natl
Acad Sci USA. 107:pp. 9446–9451. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ryu BJ, Lee H, Kim SH, Heo JN, Choi SW,
Yeon JT, Lee J, Lee J, Cho JY, Kim SH, et al: PF-3758309,
p21-activated kinase 4 inhibitor, suppresses migration and invasion
of A549 human lung cancer cells via regulation of CREB, NF-κB, and
β-catenin signalings. Mol Cell Biochem. 389:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tyner JW, Yang WF, Bankhead A III, Fan G,
Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming
WH, et al: Kinase pathway dependence in primary human leukemias
determined by rapid inhibitor screening. Cancer Res. 73:285–296.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Y, Gu TT and Zheng PS: CIP2A cooperates
with H-Ras to promote epithelial-mesenchymal transition in
cervical-cancer progression. Cancer Lett. 356:646–655. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
John-Baptiste A, Huang W, Kindt E, Wu A,
Vitsky A, Scott W, Gross C, Yang AH, Schaiff WT and Ramaiah SK:
Evaluation of potential gastrointestinal biomarkers in a PAK4
inhibitor-treated preclinical toxicity model to address
unmonitorable gastrointestinal toxicity. Toxicol Pathol.
40:482–490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen S, Auletta T, Dovirak O, Hutter C,
Kuntz K, El-ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, et
al: Copy number alterations in pancreatic cancer identify recurrent
PAK4 amplification. Cancer Biol Ther. 7:1793–1802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kesanakurti D, Chetty C, Maddirela D
Rajasekhar, Gujrati M and Rao JS: Functional cooperativity by
direct interaction between PAK4 and MMP-2 in the regulation of
anoikis resistance, migration and invasion in glioma. Cell Death
Dis. 3:e4452012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Siu MK, Chan HY, Kong DS, Wong ES, Wong
OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated
kinase 4 regulates ovarian cancer cell proliferation, migration,
and invasion and contributes to poor prognosis in patients. Proc
Natl Acad Sci USA. 107:pp. 18622–18627. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ong CC, Gierke S, Pitt C, Sagolla M, Cheng
CK, Zhou W, Jubb AM, Strickland L, Schmidt M, Duron SG, et al:
Small molecule inhibition of group I p21-activated kinases in
breast cancer induces apoptosis and potentiates the activity of
microtubule stabilizing agents. Breast Cancer Res. 17:592015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhuang T, Zhu J, Li Z, Lorent J, Zhao C,
Dahlman-Wright K and Strömblad S: p21-activated kinase group II
small compound inhibitor GNE-2861 perturbs estrogen receptor alpha
signaling and restores tamoxifen-sensitivity in breast cancer
cells. Oncotarget. 6:43853–43868. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao ZS and Manser E: Do PAKs make good
drug targets? F1000 Biol Rep. 2:702010.PubMed/NCBI
|
|
35
|
Callow MG, Clairvoyant F, Zhu S, Schryver
B, Whyte DB, Bischoff JR, Jallal B and Smeal T: Requirement for
PAK4 in the anchorage-independent growth of human cancer cell
lines. J Biol Chem. 277:550–558. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X and Minden A: PAK4 functions in tumor
necrosis factor (TNF) alpha-induced survival pathways by
facilitating TRADD binding to the TNF receptor. J Biol Chem.
280:41192–41200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X,
Lee HJ, Suh N, Yang CS and Minden A: The pak4 protein kinase plays
a key role in cell survival and tumorigenesis in athymic mice. Mol
Cancer Res. 6:1215–1224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tyagi N, Bhardwaj A, Singh AP, McClellan
S, Carter JE and Singh S: p-21 activated kinase 4 promotes
proliferation and survival of pancreatic cancer cells through AKT-
and ERK-dependent activation of NF-kappaB pathway. Oncotarget.
5:8778–8789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gnesutta N, Qu J and Minden A: The
serine/threonine kinase PAK4 prevents caspase activation and
protects cells from apoptosis. J Biol Chem. 276:14414–14419. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fu X, Feng J, Zeng D, Ding Y, Yu C and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEK/ERK-dependent pathways. Biosci Rep. 34:59–67.
2014. View Article : Google Scholar
|
